$5.23
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
How Investors Are Reacting To Annexon (ANNX) Phase 3 Tanruprubart Win And Vonaprument Updates
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
Overview
52-week range
$1.85
$7.18
63% of range
Avg surprise (last 3)
+1.9%
Avg reaction (last 2)
+3.7%
50% positive
Latest IV / EM
50%
EM ±11.5% · $5 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.23 | $-0.30 | +23.3% | +37.8% | -3.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.37 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.34 | $-0.36 | +5.6% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.37 | $-0.30 | -23.3% | — | +10.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.25 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.23 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.21 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.43 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.47 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.23 | -$0.34 | +32.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-46M | — | $-57M | $-52M | $-57M | — | $-39M | $-34M |
| Net income | $-44M | — | $-55M | $-49M | $-54M | — | $-35M | $-30M |
| EPS (diluted) | $-0.23 | — | $-0.37 | $-0.34 | $-0.37 | — | $-0.25 | $-0.23 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $175M | $162M | $139M | $132M | $97M | $49M | $80M | $157M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $228M | $242M | $193M | $231M | $268M | $316M | $344M | $374M |
| Total assets | $263M | $278M | $229M | $265M | $303M | $350M | $379M | $406M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $58M | $66M | $68M | $66M | $59M | $57M | $47M | $45M |
| Total equity | $205M | $212M | $161M | $199M | $244M | $293M | $332M | $361M |